Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc.SHPH · Entity 8505 | Chief Scientific Officer | May 01, 2024 | October 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shuttle Pharmaceuticals Holdings, Inc.
Report date May 01, 2024 · Filed October 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CLASS A COMMON STOCKSEC Table I · non-derivative | Direct | 135,715 |
Reported balance
After 2024-05-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-01 · Grant · Disposed 598 · Balance 135,715 F1: The Reporting Person received a grant of 1,791 restricted stock units ("RSUs") on May 1, 2023 (14,326 RSUs on a pre-reverse split basis), which RSUs are subject to vesting over a period of three years. The first vesting of 598 RSUs occurred on May 1, 2024. F2: Consists of (i) 134,522 shares of common stock and (ii) 1,193 RSUs which remain subject to vesting. All share and RSU numbers reflect a 1-for-8 reverse stock split effected by the issuer on August 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received a grant of 1,791 restricted stock units ("RSUs") on May 1, 2023 (14,326 RSUs on a pre-reverse split basis), which RSUs are subject to vesting over a period of three years. The first vesting of 598 RSUs occurred on May 1, 2024.
F2: Consists of (i) 134,522 shares of common stock and (ii) 1,193 RSUs which remain subject to vesting. All share and RSU numbers reflect a 1-for-8 reverse stock split effected by the issuer on August 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed Oct 9, 2024 17:00 UTC | Shuttle Pharmaceuticals Holdings, Inc. SHPH · Entity 8505 | GrantCLASS A COMMON STOCK | 598 | $11.28 | $6,745.44 |
DisclosureSEC source: 0001493152-24-040614 · ownership.xml · nonDerivative · entry 1 Jung Mira · CIK 0001945307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,715 F1 · shares: The Reporting Person received a grant of 1,791 restricted stock units ("RSUs") on May 1, 2023 (14,326 RSUs on a pre-reverse split basis), which RSUs are subject to vesting over a period of three years. The first vesting of 598 RSUs occurred on May 1, 2024. F2 · balance_after: Consists of (i) 134,522 shares of common stock and (ii) 1,193 RSUs which remain subject to vesting. All share and RSU numbers reflect a 1-for-8 reverse stock split effected by the issuer on August 13, 2024. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 06:10 UTC | Shuttle Pharmaceuticals Holdings, Inc. SHPH · Entity 8505 | SaleCLASS A COMMON STOCK | 328 | $1.61 | $526.44 |
DisclosureSEC source: 0001493152-23-000013 · ownership.xml · nonDerivative · entry 1 Jung Mira · CIK 0001945307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,388 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 892 restricted stock units ("RSUs") held by the Reporting Person. Upon vesting of the RSUs, the sales are automatic, routine, non-discretionary transactions mandated by the Issuer under its equity incentive plan in order to satisfy the Reporting Person's tax withholding obligations which are funded by "sell to cover" transactions. These transactions are exempt under Section 16b-3 and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Consists of 1,071,388 shares of SHPH common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.